Scarica l'app Stockscreener
14.81
4.08%
-0.63
Dopo l'orario di chiusura:
14.81
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 - Yahoo Finance
Cullinan Therapeutics - The Pharma Letter
CGEM Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at BTIG Research - MarketBeat
CGEM Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Singapore
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio - Investing News Network
Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances By Investing.com - Investing.com Canada
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - stocktwits.com
Cullinan Therapeutics (CGEM) Eyes Key Autoimmune and AML Data Re - GuruFocus
Cullinan delays early-stage data for arthritis drug (CGEX) - Seeking Alpha
Cullinan Therapeutics (CGEM) Shares Drop 7% as CLN-978 Data Rele - GuruFocus
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - Yahoo Finance
Cullinan Therapeutics (CGEM) Sets Q4 2026 Clinical Updates Amid High Price-to-Sales Valuation - GuruFocus
Cullinan Therapeutics Highlights Fourth Quarter 2026 - GlobeNewswire
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - Yahoo Finance
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? - Yahoo Finance
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - investingnews.com
Phase III results could broaden opportunity for Cullinan’s lead cancer drug - The Pharma Letter
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Should Phase 3 Lung Cancer Data Require Action From Cullinan Therapeutics (CGEM) Investors? - simplywall.st
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity? - Insider Monkey
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $42 - Moomoo
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $42 - Moomoo
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst CallSlideshow (NASDAQ:CGEM) 2026-09-14 - Seeking Alpha
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen - Investing.com South Africa
BTIG raises Cullinan Oncology stock price target on trial data - Investing.com
BTIG raises Cullinan Oncology stock price target on trial data By Investing.com - Investing.com Canada
Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await (CGEM) - Seeking Alpha
Stifel reiterates Cullinan Oncology stock Buy rating on trial data By Investing.com - Investing.com South Africa
Stifel reiterates Cullinan Oncology stock Buy rating on trial data - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results - Yahoo Finance
CGEM: Zipalertinib plus chemotherapy achieved unprecedented PFS and CNS efficacy in first-line EGFR exon 20 NSCLC - TradingView
Cullinan Therapeutics stock falls despite positive trial data By Investing.com - Investing.com Canada
CGEM: Zipalertinib plus chemotherapy significantly improved PFS and ORR in EGFR ex20ins NSCLC - TradingView
Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3 - TradingView
Cullinan Therapeutics to Host Virtual Investor Event on Phase 3 REZILIENT3 Zipalertinib Data from IASLC WCLC 2026 - Quiver Quantitative
Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire
Squarepoint Ops LLC Invests $3.06 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - Investing News Network
Cullinan Therapeutics (CGEM) Advances Lung Cancer Trial; Valuati - GuruFocus
Zipalertinib plus chemo shows survival benefit in lung cancer trial By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):